May 3, 2017
Acorda won at the PTAB but lost in the US District Court.
Acorda Therapeutics, Inc. is fighting is to extend the life of their 4-aminopyridine formulations and methods.
Acorda will retain market exclusivity to AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg at least through July 2018.
The US District Court in Delaware ruled that Acorda’s four patents set to expire between 2025 and 2027 are invalid. A few weeks earlier, the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld the four patents challenged via the inter partes review (IPR) process [U.S. Patent Nos. 8,663,685 (the ‘685 patent), 8,440,703 (the ‘703 patent), 8,354,437 (the ‘437 patent) and 8,007,826 (the ‘826 patent)]. These patents, if valid and enforceable, are calculated to expire in 2025, 2025, 2026 and 2027, respectively.
ACORDA THERAPEUTICS, INC., et al. v. ROXANE LABORATORIES, INC., et al.
Case #: 14-882
Judge: Chief Judge Leonard P. Stark
Next?: Acorda will appeal. Meanwhile Acorda announced restructuring and layoffs
http://cen.acs.org/articles/95/i15/Troubled-biotechs-cut-jobs.html
Fierce Pharma
http://www.fiercepharma.com/pharma/court-nixes-4-acorda-patents-teeing-up-amprya-generics-for-2018
Acorda press releases
You must be logged in to post a comment.